| Similar Articles |
|---|
 |
The Motley Fool
February 29, 2008
Brian Lawler |
NeurogesX Gets a Painful Kick in the Pants NeurogesX's lead drug fails in clinical testing.   |
The Motley Fool
July 2, 2008
Brian Lawler |
DURECT's Intriguing Little Orphan An exciting pain drug inches onward in development. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
September 18, 2009
Brian Orelli |
A 25% Stock Gain Will Ease Any Pain Glaxo and XenoPort's shingles drug gives the latter's shares a healthy boost. |
The Motley Fool
July 11, 2007
Brian Lawler |
Why Depomed Shares Were Dumped In a recent trial, a pain medication wasn't as effective as had been hoped. Investors, take note. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
June 22, 2011
Brian Orelli |
Building on Pfizer's Blockbuster New data for an expanded indication for Lyrica. |
The Motley Fool
January 22, 2007
Brian Lawler |
The Feds Eye Endo Endo Pharmaceuticals' sales practices for Lidoderm prompt government scrutiny. Investors don't seem too concerned. |
The Motley Fool
May 29, 2007
Brian Lawler |
The One Development-Stage Drug Stock to Own Now With such a low level of Remoxy sales baked into its share price, and minimal clinical trial risk, investors who consider Pain Therapeutics around today's share price won't be hurting in the long run, if you assume there will be a viable market for abuse-resistant opioids. |
The Motley Fool
January 31, 2011
Brian Orelli |
Drug Approved! Now Who's Going to Launch It? Depomed gets pain-free news from the FDA. |
The Motley Fool
April 30, 2007
Brian Orelli |
No Pain for Endo's Investors Endo Pharmaceuticals had an impressive first quarter thanks to a new product and continued sales growth of its older brands. Investors, take note. |
The Motley Fool
March 21, 2007
Brian Lawler |
New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary. |
The Motley Fool
April 7, 2011
Brian Orelli |
Restless No Longer XenoPort and Glaxo get a delayed FDA approval. |
The Motley Fool
August 3, 2007
Brian Lawler |
Endo Adjusting to Bigger Hopes The pharma announces its second-quarter financial results. As worries recede about near-term generic competition for lead drug Lidoderm, expectations for Endo have grown. |
The Motley Fool
January 30, 2008
Brian Lawler |
The Endo a CEO Shares of Endo Pharmaceutical rise after its CEO, Peter Lankau, resigns. |
The Motley Fool
November 6, 2007
Brian Lawler |
The Two Sides of Endo It has been a mixed third quarter for Endo Pharmaceuticals. On the financial side of things the company performed well; on the research and development side, things are not as good. |
The Motley Fool
October 23, 2006
Brian Lawler |
Not the End for Endo An FDA decision won't hurt the maker of Lidoderm. Investors, take note. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
BusinessWeek
December 11, 2006
Michael Arndt |
When A Winner Starts To Wane Endo is seeking to immunize itself from the slowing growth of its Lidoderm pain patch. |
The Motley Fool
December 24, 2009
Brian Orelli |
Another Reason to Worry About Pfizer The FDA fails to approve Lyrica for treating anxiety. |
The Motley Fool
January 10, 2007
Brian Lawler |
Endo's Plan to Bring In the Dough Despite little movement in the value of their shares, 2006 was an eventful year for investors in drug developer Endo Pharmaceuticals. |
The Motley Fool
November 10, 2009
Brian Orelli |
3 Companies Looking for Gratitude Early These three small drug companies all have PDUFA dates in the next week: Cadence Pharmaceuticals... NeurogesX... Genzyme... |
The Motley Fool
April 30, 2007
Brian Lawler |
Nothing Wrong With Endo Endo Pharmaceuticals releases first-quarter financial results. Investors, take note. |
The Motley Fool
January 19, 2007
Brian Lawler |
The Best Drug Stock for 2007: Endo Pharmaceuticals This drug-maker just might be a great investment at the current price. |
The Motley Fool
September 29, 2010
Brian Orelli |
A Mini-Teva in the Making Generic growth by Endo Pharmaceuticals. |
BusinessWeek
December 11, 2006
Michael Arndt |
Kills Pain, Cures Rabies, And Grows Hair The prescription drug market is one part Big Brother and one part Wild West. |
The Motley Fool
February 25, 2008
Brian Lawler |
The Yin and Yang of Endo Endo Pharmaceuticals' fiscal 2007 report offered positive year-end financial results and a little bit of balance-sheet sourness. |
BusinessWeek
January 17, 2005
Catherine Arnst |
No Pain, Some Gain The 50 million Americans suffering from chronic pain got a little bit of good news in December. The Food & Drug Administration greenlighted two new medications that attack pain in completely novel ways. |
The Motley Fool
February 26, 2007
Brian Lawler |
Endo Brings in the Dough Why buy this pharmaceutical? Investors, let me count the ways. |
The Motley Fool
August 1, 2007
Brian Lawler |
Calling Out Endo Endo Pharmaceuticals gets taken to task by an activist investor. An investment group owning 5.6% of outstanding shares is concerned with how management plans to use $700 million available to them in cash and investments. |
Managed Care
May 2005 |
Microcircuit Devices Deliver Considerable Relief From Chronic Pain Recent advances in pain relief revolve around longer-lasting implantable devices. Can managed care afford not to have a pain management strategy? |
American Family Physician
September 15, 2005
Mounsey, Matthew & Slawson |
Herpes Zoster and Postherpetic Neuralgia: Prevention and Management The recognizable appearance and the dermatomal distribution of herpes zoster (shingles) lesions usually enable a clinical diagnosis to be made easily. Herpes zoster and postherpetic neuralgia occur mainly in older patients. |
American Family Physician
October 1, 2001
Karl E. Miller |
Challenges in Pain Management at the End of Life Effective pain management in the terminally ill patient requires an understanding of pain control strategies. Ongoing assessment of pain is crucial and can be accomplished using various forms and scales... |
Health
June 2007
Melanie Haiken |
The Best New Pain Cures?... For Women New research shows that pain can often be prevented if women use the right treatment. Here's what you should know. |
Managed Care
October 2003
Martin Sipkoff |
Pain Management: Health Plans Need to Take Control Insurers have not focused much on chronic pain. They should. It presents a humanitarian and business opportunity. |
Salon.com
October 2, 2000
Lynn O'Dell |
Pain in the brain The good news? The hurt is all in your mind. The bad news? The hurt is all in your mind... |
American Family Physician
September 15, 2005 |
Shingles: Easing the Pain A patient overview of the disease, its causes and treatment options. |
Nursing
October 2009
Yvonne D'Arcy |
Overturning barriers to pain relief in older adults This article will describe how to lower the barriers to effective pain control in older patients and provide practical tips for helping them receive the full benefit from pharmacologic and nonpharmacologic therapies. |
American Journal of Nursing
April 2010
Mary Curry Narayan |
Culture's Effects on Pain Assessment and Management When patients belong to a culture or speak a language that's different from that of their health care provider, the provider faces additional challenges in successfully assessing and managing the patients' pain. |
